Youth with Attention Deficit Hyperactivity Disorder (ADHD) are at higher risk to start smoking than youth without ADHD and may have a more difficult time quitting smoking. This is especially true for youth with ADHD and other conditions such as conduct disorder, anxiety disorders, and mood disorders. This research study uses Bupropion SR, a drug currently used to treat ADHD in children and adolescents. Bupropion SR is also currently approved to help adults stop smoking.

The specific aims of the study are:

1. to select children and adolescents with ADHD who may have one or more comorbid disorders (e.g. conduct, mood, anxiety);
2. to complete a double-blind clinical trial of Bupropion SR for the prevention of smoking in high-risk ADHD adolescents;
3. to examine additional outcomes in high-risk ADHD children; and
4. to implement procedures for long-term follow-up.

Inclusion / Exclusion Criteria:

Outpatient youths of either sex between 9 and 18 years of age will be eligible for entry into the research study if they meet DSM-IV diagnostic criteria for ADHD.
In addition, they may meet DSM-IV diagnostic criteria for a lifetime history of the following: conduct disorder, major depressive disorder or multiple anxiety disorders (i.e., a history of two or more anxiety disorders).
Potential subjects will not be excluded if they are nicotine dependent or engage in daily cigarette smoking.
No ethnic or racial group will be excluded from this study.